|
1
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Buckner JC: Factors influencing survival
in high-grade gliomas. Semin Oncol. 30 (6 Suppl 19):S10–S14.
2003.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Barnholtz-Sloan JS, Williams VL, Maldonado
JL, Shahani D, Stockwell HG, Chamberlain M and Sloan AE: Patterns
of care and outcomes among elderly individuals with primary
malignant astrocytoma. J Neurosurg. 108:642–648. 2008.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Scott JG, Bauchet L, Fraum TJ, Nayak L,
Cooper AR, Chao ST, Suh JH, Vogelbaum MA, Peereboom DM, Zouaoui S,
et al: Recursive partitioning analysis of prognostic factors for
glioblastoma patients aged 70 years or older. Cancer.
118:5595–5600. 2012.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Aquilanti E, Miller J, Santagata S, Cahill
DP and Brastianos PK: Updates in prognostic markers for gliomas.
Neuro Oncol. 20 (Suppl 7):vii17–vii26. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Hegi ME, Diserens AC, Gorlia T, Hamou MF,
de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani
L, et al: MGMT gene silencing and benefit from temozolomide in
glioblastoma. N Engl J Med. 352:997–1003. 2005.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Lee SY: Temozolomide resistance in
glioblastoma multiforme. Genes Dis. 3:198–210. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Esteller M, Garcia-Foncillas J, Andion E,
Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB and Herman JG:
Inactivation of the DNA-repair gene MGMT and the clinical response
of gliomas to alkylating agents. N Engl J Med. 343:1350–1354.
2000.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Knizhnik AV, Roos WP, Nikolova T, Quiros
S, Tomaszowski KH, Christmann M and Kaina B: Survival and death
strategies in glioma cells: Autophagy, senescence and apoptosis
triggered by a single type of temozolomide-induced DNA damage. PLoS
One. 8(e55665)2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Gerber DE, Grossman SA, Zeltzman M, Parisi
MA and Kleinberg L: The impact of thrombocytopenia from
temozolomide and radiation in newly diagnosed adults with
high-grade gliomas. Neuro Oncol. 9:47–52. 2007.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Gerson SL, Phillips W, Kastan M, Dumenco
LL and Donovan C: Human CD34+ hematopoietic progenitors
have low, cytokine-unresponsive O6-alkylguanine-DNA
alkyltransferase and are sensitive to O6-benzylguanine plus BCNU.
Blood. 88:1649–1655. 1996.PubMed/NCBI
|
|
12
|
Stokes JE, Bobola MS, Chamberlain MC and
Silber JR: Low leukocyte MGMT accompanies temzolomide-induced
myelotoxicity in brain tumor patients. J Can Res Updates. 1:44–48.
2012.
|
|
13
|
Abola MV, Prasad V and Jena AB:
Association between treatment toxicity and outcomes in oncology
clinical trials. Ann Oncol. 25:2284–2289. 2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Di Maio M, Gridelli C, Gallo C, Shepherd
F, Piantedosi FV, Cigolari S, Manzione L, Illiano A, Barbera S,
Robbiati SF, et al: Chemotherapy-induced neutropenia and treatment
efficacy in advanced non-small-cell lung cancer: A pooled analysis
of three randomised trials. Lancet Oncol. 6:669–677.
2005.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Vaios EJ, Nahed BV, Muzikansky A, Fathi AT
and Dietrich J: Bone marrow response as a potential biomarker of
outcomes in glioblastoma patients. J Neurosurg. 127:132–138.
2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Saito T, Sugiyama K, Hama S, Yamasaki F,
Takayasu T, Nosaka R, Muragaki Y, Kawamata T and Kurisu K:
Prognostic importance of temozolomide-induced neutropenia in
glioblastoma, IDH-wildtype patients. Neurosurg Rev. 41:621–628.
2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ho KG, Uhlmann EN, Wong ET and Uhlmann EJ:
Leukopenia is a biomarker for effective temozolomide dosing and
predicts overall survival of patients with glioblastoma. Mol Clin
Oncol. 13(80)2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Le Rhun E, Oppong FB, Vanlancker M, Stupp
R, Nabors B, Chinot O, Wick W, Preusser M, Gorlia T and Weller M:
Prognostic significance of therapy-induced myelosuppression in
newly diagnosed glioblastoma. Neuro Oncol. 24:1533–1545.
2022.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Humphries W, Wei J, Sampson JH and
Heimberger AB: The role of tregs in glioma-mediated
immunosuppression: Potential target for intervention. Neurosurg
Clin N Am. 21:125–137. 2010.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Williams M, Liu ZW, Woolf D, Hargreaves S,
Michalarea V, Menashy R, Kooner I and Wilson E: Change in platelet
levels during radiotherapy with concurrent and adjuvant
temozolomide for the treatment of glioblastoma: A novel prognostic
factor for survival. J Cancer Res Clin Oncol. 138:1683–1688.
2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Marx S, Xiao Y, Baschin M, Splittstöhser
M, Altmann R, Moritz E, Jedlitschky G, Bien-Möller S, Schroeder HWS
and Rauch BH: The role of platelets in cancer pathophysiology:
Focus on malignant glioma. Cancers (Basel). 11(569)2019.PubMed/NCBI View Article : Google Scholar
|
